workshop
viral
vector
malaria
vaccin
develop
organ
path
malaria
vaccin
initi
held
bethesda
md
octob
recent
advanc
viralvector
malaria
vaccin
develop
emerg
vector
technolog
present
discuss
classic
viral
vector
poxviru
adenoviru
alphaviru
vector
success
use
deliv
malaria
antigen
vaccin
candid
demonstr
potenti
induc
malariaspecif
immun
anim
model
human
trial
addit
emerg
viralvector
technolog
measl
viru
mv
vesicular
stomat
viru
vsv
yellow
fever
yf
viru
may
also
use
malaria
vaccin
develop
studi
anim
model
suggest
viral
vector
uniqu
abil
induc
humor
andor
cellular
immun
respons
studi
also
reveal
optim
plasmodium
gene
mammalian
express
import
aspect
vaccin
design
codonoptim
surfacetraffick
deglycosyl
remov
toxic
domain
lead
improv
immunogen
understand
vector
abil
induc
immun
respons
express
malaria
antigen
mammalian
cell
critic
design
next
gener
viralvector
malaria
vaccin
publish
elsevi
ltd
malaria
signific
caus
morbid
mortal
affect
billion
peopl
worldwid
estim
malaria
respons
annual
death
one
million
peopl
mostli
children
age
five
effect
malaria
vaccin
urgent
need
control
diseas
major
obstacl
develop
effect
malaria
vaccin
includ
complex
life
cycl
antigen
divers
parasit
despit
challeng
encourag
result
report
recent
rt
preerythrocyt
circumsporozoit
protein
csp
base
vaccin
lead
candid
demonstr
protect
clinic
malaria
adult
phase
experiment
challeng
studi
african
children
phase
field
trial
tradit
approach
malaria
vaccin
develop
base
recombin
protein
howev
one
main
challeng
recombin
proteinbas
vaccin
protein
poorli
immunogen
mani
recombin
proteinbas
vaccin
requir
addit
adjuv
boost
immun
respons
especi
immun
respons
desir
experiment
malaria
vaccin
current
use
adjuv
yet
use
licens
vaccin
addit
mani
antigen
target
highli
structur
proper
conform
seem
requir
gener
function
immun
respons
lead
challeng
develop
purif
process
refold
isol
proper
conform
often
result
complex
manufactur
process
low
yield
anoth
challeng
longterm
stabil
recombin
protein
formul
adjuv
ambient
temperatur
viral
vector
hand
appear
capabl
induc
antibodi
tcellmedi
immun
absenc
adjuv
furthermor
complex
process
develop
may
requir
viralvector
vaccin
usual
consist
purif
process
irrespect
transgen
express
vaccin
use
eukaryot
cellular
machineri
gener
antigen
target
may
possibl
gener
antigen
nativ
conform
final
viral
vector
capac
deliv
one
gene
thu
singl
viral
vector
construct
may
contain
multipl
antigen
differ
parasit
life
stage
would
potenti
induc
broad
protect
immun
signific
manufactur
cost
save
could
also
realiz
viral
vector
use
vaccin
develop
decad
although
earlier
studi
gener
mix
result
recent
substanti
advanc
appli
viral
vector
toward
malaria
vaccin
develop
vaccin
progress
phase
efficaci
test
african
children
viralvector
vaccin
shown
efficaci
malaria
vaccin
trial
human
far
diseas
time
signific
progress
made
develop
new
viralvector
technolog
use
develop
hiv
vaccin
facilit
applic
viral
vector
malaria
vaccin
develop
path
malaria
vaccin
initi
mvi
organ
workshop
viral
vector
malaria
vaccin
develop
purpos
workshop
share
experi
vector
technolog
malaria
vaccin
develop
could
valuabl
design
next
gener
effect
viralvector
malaria
vaccin
poxvirus
known
induc
longlast
immun
larg
express
capac
poxvirus
make
popular
choic
malaria
vaccin
develop
vaccinia
viru
express
csp
studi
ortholog
plasmodium
berghei
rodent
model
although
vaccin
reduc
parasit
load
liver
abil
confer
steril
protect
modest
howev
immun
protocol
use
recombin
influenza
viru
primer
recombin
pox
viru
booster
plasmodium
yoelii
rodent
model
induc
larg
tcell
respons
high
degre
steril
immun
demonstr
high
effici
heterolog
primeboost
immun
protocol
first
time
overcom
shortfal
singl
antigenexpress
vaccinia
viru
poxvirusvector
multiantigen
multistag
vaccin
candid
develop
nyvac
highli
attenu
vaccinia
viru
strain
deriv
copenhagen
vaccin
express
plasmodium
p
falciparumderiv
csp
trombospondinrel
adhes
protein
trap
liverstag
antigen
merozoit
surfac
protein
apic
membran
antigen
serin
repeat
antigen
sera
vaccin
candid
test
phase
human
trial
immun
respons
antigen
except
sera
detect
although
titer
low
vaccin
dose
plaqu
form
unit
pfu
appear
immunogen
pfu
preexist
immun
vaccinia
viru
appear
capabl
modul
immunogen
immun
subject
subsequ
challeng
p
falciparuminfect
mosquito
one
immun
patient
fulli
protect
challeng
averag
delay
prepat
period
detect
vaccine
addit
nyvac
attenu
poxvirus
modifi
vaccinia
viru
ankara
mva
fowlpox
strain
use
deliv
malaria
antigen
mva
anoth
highli
attenu
vaccinia
viru
strain
undergo
limit
replic
human
cell
attenu
avipoxviru
particularli
effect
induc
tcell
respons
mva
express
csp
trap
induc
modest
level
protect
rodent
malaria
model
howev
combin
dna
vaccin
heterolog
primeboost
regimen
recombin
mva
express
csp
trap
induc
high
level
tcell
respons
provid
protect
challeng
sporozoit
rodent
malaria
p
berghei
metrap
malaria
vaccin
candid
encod
trap
multipl
malaria
epitop
deriv
differ
preerythrocyt
stage
antigen
express
mva
vaccin
candid
test
human
phase
challeng
trial
homolog
heterolog
primeboost
regimen
heterolog
primeboost
effect
induc
tcellmedi
immun
reduc
parasit
load
repres
calcul
reduct
liverstag
parasit
memori
tcell
assess
cultur
elispot
assay
strongli
associ
delay
prepat
period
effector
cell
measur
elispot
assay
two
five
volunt
receiv
heterolog
regim
challeng
less
month
final
vaccin
fulli
protect
sporozoit
challeng
one
two
volunt
fulli
protect
second
sporozoit
challeng
month
postimmun
third
challeng
month
final
vaccin
mvametrap
regim
safe
immunogen
west
african
adult
kenyan
children
phase
efficaci
trial
heterolog
primeboost
regimen
kenyan
children
start
earli
av
hill
person
commun
contrast
metrap
csp
express
mva
poorli
immunogen
human
protect
detect
heterolog
primeboost
regimen
polypeptid
compos
sporozoit
threonin
asparginerich
protein
starp
export
protein
trap
also
express
mva
expect
enter
phase
studi
studi
anim
model
demonstr
six
antigen
candid
immunogen
addit
util
vector
data
mice
indic
poxviru
enhanc
immunogen
recombin
proteinbas
vaccin
coadministr
indic
viru
may
capabl
act
adjuv
find
rais
intrigu
prospect
use
vector
vaccin
deliv
malaria
antigen
simultan
serv
immunostimul
recombin
protein
replicationdefici
adenoviru
vector
wide
use
develop
vaccin
varieti
infecti
diseas
signific
advanc
use
adenoviru
vector
develop
hiv
vaccin
particular
tcellbas
vaccin
rodent
malaria
model
p
yoelii
shown
adenoviru
vector
express
csp
excel
induc
tcell
antibodi
respons
induc
protect
sporozoit
challeng
p
yoelii
model
combin
experiment
adenovirusvector
malaria
vaccin
express
csp
p
falciparum
schedul
test
human
homolog
heterolog
primeboost
immun
regimen
dna
vaccin
dl
doolan
person
commun
adenoviru
vector
also
current
use
develop
two
secondgener
multiantigen
multistag
malaria
vaccin
one
vaccin
contain
bloodstag
antigen
contain
three
preerythrocyt
antigen
csp
trap
malaria
antigen
optim
express
mammalian
cell
immunogen
anim
model
known
signific
differ
protein
synthesi
protozoan
mammalian
cell
exampl
codonusag
plasmodium
gene
differ
mammalian
gene
codonoptim
significantli
increas
express
level
plasmodium
antigen
mammalian
cell
addit
glycosylphosphatidylinositol
gpi
anchor
attach
antigen
parasit
surfac
nativ
p
falciparum
protein
glycosyl
howev
p
falciparum
contain
multipl
potenti
nand
olink
glycosyl
site
report
one
studi
nglycosyl
mammalian
cell
decreas
protect
immun
respons
nonhuman
primat
wherea
oglycosyl
appear
effect
function
antigen
studi
therefor
conduct
determin
whether
remov
nglycosyl
site
lead
increas
immunogen
adenovirusvector
bloodstag
vaccin
mani
plasmodi
surfac
protein
anchor
gpi
appear
poorli
process
mammalian
cell
exampl
gpi
function
well
eukaryot
may
one
main
reason
nativ
transport
poorli
surfac
mammalian
cell
attempt
made
replac
plasmodi
gpi
signal
sequenc
mammalian
sequenc
improv
immunogen
adenovirusvector
vaccin
also
presenc
gpi
signal
sequenc
appear
interfer
protein
express
exampl
gpi
signal
sequenc
csp
shown
affect
protein
express
vitro
immunogen
rodent
model
sitedirect
mutagenesi
conduct
reduc
antigenrel
toxic
improv
immunogen
preerythrocyt
stage
vaccin
addit
use
singl
adenoviru
vector
express
multipl
antigen
use
differ
promot
studi
preliminari
studi
suggest
rsv
promot
exhibit
reduc
gene
express
immunogen
anim
model
compar
cytomegaloviru
cmv
promot
j
bruder
person
commun
data
suggest
select
particular
promot
play
import
role
adenovirusvector
malaria
vaccin
major
challeng
adenoviru
vector
vaccin
develop
preexist
immun
adenoviru
type
prototyp
adenoviru
vector
preexist
immun
shown
reduc
immunogen
adenovirusvector
vaccin
anim
model
seropreval
high
africa
overcom
preexist
immun
new
adenoviru
vector
base
serotyp
develop
seropreval
significantli
lower
africa
exampl
seropreval
vector
produc
k
cell
cell
line
modifi
express
k
protein
cell
cell
line
current
use
cgmp
manufactur
experiment
vaccin
effici
transduc
human
antigenpres
cell
express
csp
p
yoelii
test
mice
shown
highli
immunogen
protect
preexist
immun
viru
inhibit
immunogen
vaccin
vector
express
csp
p
falciparum
test
rhesu
macaqu
induc
strong
tand
bcellimmun
respons
interestingli
contrast
vector
vector
effici
homolog
primeboost
studi
primat
construct
schedul
test
human
addit
new
candid
express
polypeptid
contain
csp
starp
p
falciparum
construct
futur
work
determin
whether
three
malaria
antigen
act
synergist
induc
protect
immun
studi
suggest
less
immunogen
vector
anim
model
may
due
lack
high
affin
receptor
vector
human
protein
anim
system
effort
improv
immunogen
vaccin
one
approach
exchang
fiber
structur
result
improv
immunogen
vaccin
rodent
model
addit
simian
adenovir
vector
studi
overcom
preexist
immun
preliminari
studi
use
metrap
suggest
simian
adenoviru
vector
effici
induc
restrict
tcell
respons
intranas
administr
vaccin
appear
immunogen
offer
potenti
overcom
preexist
immun
vector
influenza
vaccin
base
adenoviru
vector
studi
human
rout
appear
effect
induc
antibodi
respons
inocul
dose
particl
unit
would
interest
see
whether
higher
immun
dose
result
improv
immunogen
alphaviru
posit
sens
rna
viru
replicationdefect
vector
also
refer
replicon
particl
develop
use
three
differ
virus
semliki
forest
viru
sfv
sindbi
viru
venezuelan
equin
enceph
vee
viru
replicon
particl
excel
induct
humor
cellular
immun
respons
doublestrand
rna
gener
replic
vector
may
act
immunostimulatori
adjuv
alphaviru
vector
use
deliv
antigen
vaccin
varieti
diseas
includ
malaria
anim
model
homolog
immun
regimen
sfv
replicon
particl
effici
induc
antibodi
tcellmedi
immun
howev
challeng
alphaviru
replicon
particl
technolog
lack
cgmpgrade
product
cell
line
although
current
electroporationbas
manufactur
process
capabl
produc
cgmpgrade
vaccin
human
trial
technic
hurdl
overcom
method
suitabl
commerci
manufactur
addit
replicon
technolog
alphavirus
use
vaccin
vector
form
nake
rna
dna
plasmid
dna
express
alphaviru
replicas
induc
significantli
higher
level
immun
respons
compar
plasmid
dna
without
replicas
similar
poxviru
sfv
particl
also
provid
adjuv
effect
coadminist
vaccin
abil
differ
vector
induc
cellmedi
immun
cmi
antibodi
respons
studi
rodent
malaria
model
adenoviru
alphaviru
poxviru
dna
vector
express
p
yoelii
csp
model
antigen
evalu
mice
homolog
heterolog
primeboost
regimen
homolog
regimen
adenoviru
effici
induc
cellmedi
immun
wherea
poxviru
least
effici
vector
prime
cmi
heterolog
regimen
adenoviru
effici
prime
boost
cmi
respons
poxviru
vector
excel
boost
cmi
poor
prime
cmi
respons
alphaviru
replicon
effici
prime
cmi
less
effect
boost
cmi
dl
doolan
person
commun
abil
vector
prime
boost
antibodi
respons
similar
describ
cmi
notabl
differ
alphaviru
replicon
excel
prime
boost
antibodi
respons
fact
homolog
alphaviru
immun
effici
heterolog
immun
regimen
regard
induct
antibodi
respons
protect
immun
also
studi
p
yoelii
rodent
malaria
model
immun
regimen
includ
poxviru
vector
boost
result
highest
level
protect
immun
howev
protect
immun
appear
shortliv
signific
reduct
protect
month
postimmun
contrast
prime
adenoviru
boost
alphaviru
vector
result
longterm
protect
immun
strong
correl
interferon
respons
protect
sporozoit
challeng
dl
doolan
person
commun
anoth
studi
differ
vector
express
ctl
epitop
syvpsaeqi
deriv
csp
p
yoelii
compar
rodent
model
adenoviru
vector
excel
induct
tcell
respons
alphaviru
replicon
also
effici
induc
tcell
respons
wherea
vaccinia
viru
poor
induc
cmi
result
agreement
data
obtain
use
csp
describ
abil
differ
vector
boost
immun
respons
evalu
mice
prime
sporozoit
vaccinia
vector
excel
boost
tcell
respons
adenoviru
vector
less
effect
boost
tcell
respons
induc
sporozoit
f
zavala
person
commun
studi
immunogen
differ
vector
reveal
magnitud
tcell
respons
defin
elispot
assay
fac
analysi
alway
correl
antiparasit
activ
prime
tcell
may
explain
least
part
recent
find
indic
memori
tcell
heterogen
popul
consist
differ
memori
cell
subset
distinct
function
properti
certain
viral
system
central
memori
subset
identifi
main
mediat
protect
studi
use
p
yoelii
system
indic
protect
memori
tcell
belong
effector
peripher
cell
subset
resid
preferenti
nonlymphoid
organ
liver
also
import
fact
memori
tcell
ident
epitop
specif
may
sharpli
differ
regard
protect
capac
thu
emphas
urgent
need
defin
new
relev
criteria
evalu
tcell
respons
induc
vaccin
candid
yellow
fever
yf
viru
prototyp
flaviviru
yf
strain
licens
live
attenu
vaccin
strain
shown
safe
infant
older
month
age
singl
dose
yf
provid
lifelong
immun
yf
use
vector
develop
vaccin
flavivirus
japanes
enceph
je
west
nile
wn
dengu
virus
vaccin
approach
includ
exchang
coat
protein
gene
yf
viru
correspond
gene
flavivirus
chimer
vaccin
shown
safe
anim
model
three
chimer
vaccin
je
wn
test
phase
human
trial
tp
monath
person
commun
yf
viru
also
use
express
heterolog
nonflaviviru
gene
insert
nonstructur
region
select
site
e
gene
yf
viru
express
ctl
epitop
p
yoelii
shown
reduc
parasit
load
rodent
malaria
model
addit
repeat
sequenc
p
falciparum
csp
insert
fg
loop
e
protein
result
viru
capabl
induc
anticsp
antibodi
rodent
model
current
express
capac
yf
kb
limit
may
present
challeng
express
fulllength
malaria
antigen
anoth
challeng
use
yf
viru
malaria
vaccin
develop
contraind
use
infant
younger
month
age
age
group
yf
might
use
booster
heterolog
primeboost
immun
regimen
measl
viru
mv
nonseg
negativestrand
rna
viru
edmonstonzagreb
strain
live
attenu
mv
wide
use
vaccin
pediatr
popul
excel
safeti
efficaci
record
revers
genet
technolog
mv
well
establish
mv
use
express
antigen
deriv
siv
hiv
hepat
b
mump
wn
viru
sarscov
studi
recombin
mv
express
heterolog
antigen
appear
induc
specif
humor
neutral
antibodi
transgen
mous
model
mv
express
hiv
gag
env
capabl
induc
cellular
immun
respons
protein
moreov
transgen
mice
macaqu
mv
express
capabl
induc
antihiv
antibodi
respons
presenc
preexist
immun
mv
mv
express
p
falciparum
investig
use
malaria
vaccin
develop
jf
viret
person
commun
due
establish
safeti
profil
mv
vaccin
recommend
young
infant
age
month
addit
sever
report
establish
safeti
vaccin
children
aerosol
applic
context
approv
mv
vaccin
aerosol
would
open
way
toward
applic
younger
infant
even
presenc
preexist
matern
antibodi
therefor
use
mv
malaria
vaccin
develop
investig
abil
protect
infant
children
ad
benefit
simultan
immun
measl
one
high
prioriti
expand
program
immun
altern
mv
may
also
use
booster
heterolog
primeboost
regim
young
infant
vesicular
stomat
viru
vsv
nonseg
negativestrand
rna
viru
famili
rhabdovirida
natur
arthropod
like
reservoir
vsv
howev
viru
also
transmit
livestock
caus
vesicular
lesion
skin
around
mouth
nostril
teat
human
infect
wild
type
wt
vsv
rare
consequ
low
vsv
seropreval
human
popul
vsv
infect
human
either
asymptomat
may
result
mild
selflimit
flulik
ill
becam
possibl
recov
vsv
genom
cdna
potenti
recombin
vsv
rvsv
vaccin
vector
explor
shiv
challeng
model
demonstr
rvsv
express
siv
gag
hiv
env
provid
signific
protect
develop
aid
nonhuman
primat
nhp
howev
result
exploratori
neurovirul
nv
studi
nhp
indic
rvsv
insuffici
attenu
human
test
nv
phenotyp
repres
potenti
obstacl
regulatori
approv
rvsv
vaccin
vector
address
problem
varieti
strategi
develop
gener
attenu
rvsv
vector
result
effort
two
rvsv
mutant
n
gene
transloc
first
fourth
posit
genom
cytoplasm
tail
ct
attach
g
protein
truncat
amino
acid
either
one
nine
amino
acid
respect
gener
shown
caus
minim
neuropatholog
subsequ
nhp
nv
studi
surprisingli
highli
attenu
rvsv
vector
express
hiv
gag
shown
immunogen
much
virul
prototyp
rvsvgag
vector
follow
intramuscular
inocul
mice
attenu
vector
also
elicit
cellular
immun
respons
nhp
equival
magnitud
respons
elicit
prototyp
rvsvgag
vector
clark
person
commun
viral
vector
excel
deliveri
vehicl
malaria
antigen
understand
uniqu
properti
individu
vector
induc
humor
cellular
immun
import
aspect
vaccin
design
classic
vaccinia
viru
vector
appear
less
effect
prime
immun
respons
excel
boost
immun
respons
like
vaccinia
viru
vector
use
heterolog
primeboost
regimen
combin
vector
dnaproteinbas
vaccin
replicationdefici
adenoviru
vector
shown
excel
prime
boost
immun
respons
particular
gener
cellular
immun
respons
therefor
may
prefer
vehicl
tcellbas
vaccin
howev
adenovirusvector
vaccin
base
therefor
overcom
preexist
immun
adenoviru
vector
may
critic
vaccin
develop
alphaviru
vector
shown
excel
induc
antibodi
respons
anim
model
may
use
blood
stage
sexual
stage
malaria
vaccin
demonstr
antibodi
respons
associ
inhibit
parasit
growth
howev
cgmp
manufactur
product
cell
line
need
alphaviru
vector
current
product
process
use
electropor
unlik
suitabl
commerci
manufactur
new
emerg
vector
provid
addit
opportun
design
new
malaria
vaccin
candid
contrast
classic
replicationdefici
viral
vector
vector
measl
viru
yellow
fever
viru
vsv
replic
vector
small
genom
therefor
level
antigen
express
like
high
furthermor
vector
measl
viru
yellow
fever
viru
base
pediatr
vaccin
proven
safeti
immunogen
profil
howev
use
replic
viral
vector
pose
challeng
safeti
immunogen
target
popul
young
infant
nonetheless
vector
explor
develop
malaria
vaccin
ration
optim
vector
malaria
vaccin
also
depend
understand
process
particular
malaria
antigen
mammalian
cell
case
gene
may
benefit
codonoptim
mimic
mammalian
usag
remov
nglycosyl
site
evalu
mainten
conform
antigen
nativ
protein
protein
target
antibodi
respons
may
need
exchang
signal
peptid
anchor
sequenc
mammalianlik
signal
facilit
transport
cell
surfac
final
plasmodi
antigen
may
toxic
vector
mammalian
cell
sitedirect
mutagenesi
may
necessari
reduc
toxic
use
viral
vector
develop
multistag
multiantigen
vaccin
provid
use
inform
synergi
protect
immun
andor
immunolog
interfer
amongst
differ
antigen
addit
studi
fundament
immun
respons
induc
viral
vector
may
also
help
us
identifi
correl
protect
design
next
gener
effect
vaccin
